Introduction: Comparative transcriptome analyses in Alzheimer's disease (AD) and other neurodegenerative proteinopathies can uncover both shared and distinct disease pathways. Methods: We analyzed 940 brain transcriptomes including patients with AD, progressive supranuclear palsy (PSP; a primary tauopathy), and control subjects. Results: We identified transcriptional coexpression networks implicated in myelination, which were lower in PSP temporal cortex (TCX) compared with AD. Some of these associations were retained even after adjustments for brain cell population changes. These TCX myelination network structures were preserved in cerebellum but they were not differentially expressed in cerebellum between AD and PSP. Myelination networks were downregulated in both AD and PSP, when compared with control TCX samples. Discussion: Downregulation of myelination networks may underlie both PSP and AD pathophysiology, but may be more pronounced in PSP. These data also highlight conservation of transcriptional networks across brain regions and the influence of cell type changes on these networks.
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Introduction
Many neurodegenerative diseases, including Alzheimer's disease (AD), are proteinopathies with common features including abnormal deposits of endogenous proteins, which propagate through the central nervous system (CNS) and culminate in cellular dysfunction and death, leading to clinical syndromes of dementia and/or movement disorders (reviewed [1] ). Despite their commonalities, key differences are thought to exist in the events that trigger one proteinopathy versus another and in the downstream pathophysiological pathways that distinguish these neurodegenerative diseases. Gene expression profiling studies may discover genes implicated in neurodegenerative diseases and uncover the complex molecular pathways leading to these disorders [2, 3] . With few exceptions [4] [5] [6] [7] [8] , previous studies have investigated differential gene expression (DGE) in relatively small cohorts and were limited to comparison of individual gene transcripts rather than systems-level analysis. Furthermore, most studies assessed one disease group against control subjects rather than pursuing comparison between different diseases.
We postulate that comparison of brain gene expression levels in different neurodegenerative proteinopathies can uncover molecular pathways that are common to and those that are distinct for these diseases. Discovery of brain transcriptional networks with differential expression between different proteinopathies may uncover molecular pathways that may differentially influence these conditions. In contrast, networks that have similar expression changes in different diseases in comparison to control subjects may point to common dysregulated molecular pathways.
To test this hypothesis, we focused on two distinct proteinopathies, AD [9, 10] and progressive supranuclear palsy (PSP) [11, 12] . Although brain tau protein accumulation is a neuropathologic hallmark in both, these conditions are distinguished by different predominant tau isoform aggregates [13] , and the unique presence in AD [9] , of senile plaques composed predominantly of amyloid b (Ab). They also have distinct clinical presentations. AD is the most common type of dementia [10] , whereas PSP is a relatively rare parkinsonian movement disorder [12] .
To identify genes and networks that are differentially altered in these conditions, we performed DGE and coexpression network analysis [14] , in brain transcriptome [15] [16] [17] , of subjects with AD or PSP. To determine whether observed network differences are driven by changes in AD versus PSP or different extent of change in both, we also compared each diagnostic group with elderly control samples without any neurodegenerative diagnoses. All coexpression modules (CEMs) were tested for enrichment of CNS cell types [18] , to identify altered networks that may be indicative of selectively vulnerable cell populations. Furthermore, to determine the contribution of cell population changes to our findings [19] , we performed all network analyses using two models: comprehensive model, which adjusted for levels of five CNS cell-specific transcripts, and simple model, which was not thus adjusted. Finally, we validated these results by protein analysis in brain tissue.
Our findings reveal conserved brain myelination networks that are altered in both AD and PSP, but to a greater extent in the latter. These results have implications for the role of myelin metabolism in the pathophysiology of these distinct neurodegenerative proteinopathies and ultimately for identification of novel therapeutic targets and biomarkers. Furthermore, our large-scale transcriptome data, which we made available to the research community [16] , provide information regarding brain region conservation and CNS cell-enrichment of transcriptional networks, as well as the influence of cell population changes on their expression patterns.
Methods
Please also refer to Supplementary Methods for details.
Subjects and samples
In a two-stage design, Mayo Clinic brain expression genome-wide association study (eGWAS) was used as the discovery cohort and Mayo Clinic RNA sequencing (RNAseq) samples were used as the replication cohort. The discovery cohort [15, 16] had whole genome complementary DNA-mediated annealing, selection, extension, and ligation (WG-DASL) array-based transcriptome measurements, whereas the replication cohort [16, 17] had RNAseq data obtained with 101 base pairs, paired-end sequencing on Illumina HiSeq2000 instruments, as previously published. The discovery cohort had whole genome genotypes from the Illumina HumanHap300-Duo Genotyping BeadChips [20] , and the replication cohort from the Illumina Infinium HumanOmni2.5-8 BeadChip, which were used in quality control (QC).
Analyses

Differential gene expression
DGE analyses of brain tissue from subjects of two diagnostic categories were conducted with multivariable linear regression conducted in R. Discovery cohort DGE analyses used normalized gene expression measures as dependent variable, diagnosis as independent variable of primary interest and included age at death, gender, number of APOE ε4 alleles, plate, RNA integrity number (RIN), and (RIN 2 RINmean) 2 as biological and technical covariates. Replication cohort DGE analyses used conditional quantile normalized [21] gene expression measures as dependent variable, diagnosis as independent variable of primary interest, and included age at death, gender, RIN, brain tissue source, and flow cell as biological and technical covariates. We also included cell-specific gene levels as covariates to account for neuronal loss, gliosis, and/or vascular tissue, as previously described [22] . We did this correction by including as covariates, expression levels of genes (Probe ID; ENCODE ID) that are specific for the main five cell types present in the CNS: ENO2 for neurons (ILMN_1765796, ENSG00000111674), GFAP for astrocytes (ILMN_1697176, ENSG00000131095), CD68 for microglia (ILMN_2267914, ENSG00000129226), OLIG2 for oligodendrocytes (ILMN_1727567, ENSG00000205927), and CD34 for endothelial cells (ILMN_1732799, ENSG00000174059). Significance accounting for multiple testing was assigned using q values, which are based on Benjamini-Hochberg false discovery rates [23] .
Unique genes representing probes with a q value ,0.05 for the discovery cohort temporal cortex (TCX) DGE analyses were assessed for enrichment of pathways and gene ontology (GO) biological processes using Metacore (Thompson Reuters) [24, 25] .
Weighted gene coexpression network analysis
Weighted gene coexpression network analysis (WGCNA) R package [14] , version 1.41, was used for both cohorts independently. In all analyses, gene expression residuals obtained after multiple linear regression with independent variables were input to WGCNA. Network analyses were run under two different models: "comprehensive model," which adjusts for all covariates described in Section 2.2.1 and "simple model," which adjusts for the same covariates except for the five CNS cell-specific gene expression levels.
Networks were built using two diagnostic groups to analyze their associations with diagnosis. For each pairwise diagnostic group, consensus modules were identified and tested for (GO) enrichment in WGCNA. All modules were further annotated for enrichment of genes that are primarily expressed in one of the five major cell types that exist in the CNS, that is, neurons, oligodendrocytes, microglia, astrocytes, and endothelia, as described in Section 2.2.3.
Eigengene, the first signed principal component, was calculated for each module. For each gene, module membership (MM) was calculated as the correlation between the gene and the module eigengene. Genes with MM 0.7 are considered to be "important (hub)" genes for the network. To test the association of disease phenotype with network modules, eigengenes of consensus modules were correlated with the binary disease phenotype. Unless otherwise specified, "correlation" means Pearson correlation. Preservation of different networks was assessed using WGCNA "modulePreservation" function with 100 permutations to calculate a Zsummary score, which indicates well preservation if .10.
Cell-enrichment analyses
Gene expression measures from purified cell populations, isolated from human brain tissue, were obtained from Zhang et al. [18] . We analyzed the 21,390 genes that remained after removal of those that had expression changes due to technical issues or duplicates. Genes with a mean gene expression level, fragments per kilobase per million .5 in the target cell and a fold change .4 when compared with each other cell type, were deemed to be enriched for that target cell. All CEMs were tested for enrichment for each of the five human brain cell-enriched genes using a onesided Fisher's test.
Protein analysis
We investigated brain protein levels for the key genes from the oligodendroglial networks and other genes of interest using Western blot analysis. We assessed human TCX brain tissue from 18 control subjects against either 20 PSP or 20 AD cases, in addition to two control samples measured for every protein on every gel to control for potential blot-toblot variability. Differential protein analysis was also conducted for key myelin genes from the oligodendroglial networks using proteome data obtained from 84 AD and 83 PSP TCX samples from the Mayo Clinic RNAseq replication cohort. Myelination patterns were assessed in a subset of AD, PSP, and control TCX samples (four each) using established immunohistochemistry methods [26, 27] . We evaluated immunocytochemical patterns for the myelin and oligodendrocyte proteins using rat oligodendrocyteenriched cultures [28] .
Results
Brain transcriptome profiling in the discovery cohort identifies transcriptional changes in neurodegenerative diseases in the TCX
To determine differentially expressed (DE) genes between human brains with AD versus PSP, we used whole transcriptome data from our "Mayo eGWAS discovery cohort" [15, 16] . Expression levels were obtained from TCX, which is typically affected by AD neuropathology but spared in PSP, and from the cerebellar cortex (CER), which is relatively spared in AD [9] , whereas the superior cerebellar peduncle and the dentate nucleus may be affected in PSP [12] . After QC (Supplementary Figs. 1-3 ) [15, 20] , 359 subjects with WG-DASL microarray expression measures from TCX (181 AD, 178 without AD pathology, i.e., nAD including 97 PSP) and 343 with CER (173 AD, 170 nAD including 96 PSP) were retained (Supplementary Table 1 ). There were 17,902 WG-DASL probes (13, 928 unique genes) that were expressed in .50% of all TCX samples analyzed and 17,122 such probes (13,440 unique genes) for CER samples (Supplementary Table 2 ).
We performed DGE using the comprehensive model, which includes adjustment for levels of five genes that have cell-specific expression for the main cell types present in the CNS [18] , as previously described [22, 29] . The rationale for this cell-type adjustment was to account for brain cell population changes that can occur in CNS diseases as a result of neuronal loss or gliosis, which can then influence transcriptome profiling outcomes [19] (Supplementary Results). Indeed, we identified significantly lower ENO2, but higher GFAP, CD68, and CD34 levels in the TCX, but not the CER, of AD subjects in comparison to those without AD pathology ( Supplementary Figs. 4A and B), consistent with known cellular changes that occur in affected brain regions in AD [30, 31] .
DGE results for all pairwise diagnostic comparisons are presented in Supplementary Tables 3 to 10 and Supplementary Text. There were 3381 transcripts (3094 unique genes) with significant DE in the TCX AD versus PSP analysis (Supplementary Table 4 ). In contrast, there were only six significant probes in the CER AD versus PSP DGE analyses (Supplementary Table 6 ). DGE results in the discovery cohort suggested strong transcriptional changes in the TCX but not CER for all diagnostic comparisons.
Pathway enrichment analysis of the most significant DEGs in the AD versus PSP TCX analysis (3094 genes, q , 0.05) implicated 66 enriched GO and MetaCore pathways with a false discovery rate ,0.05, including established pathways such oxidative phosphorylation, where a systematic downregulation in AD TCX of genes in this pathway is observed (Supplementary Table 11 , Supplementary Fig. 5 ), replicating prior observations [21, 28] . In the smaller AD versus nTau analysis (572 genes) "Protein folding and maturation_POMC (proopiomelanocortin) processing" was a significant MetaCore pathway, also detected in the AD versus PSP analysis. Assessment of the 745 unique genes DE in PSP versus nTau (without primary tau or AD pathology, i.e., nonTau) TCX, detected three significant and overlapping GO processes: "axon ensheathment in CNS," "CNS myelination," and "oligodendrocyte development."
Coexpression network analysis in the discovery cohort identifies modules that are enriched for specific brain cell types
We constructed coexpression networks [14] , under both the comprehensive and simple models, where the latter was implemented given the observed correlation of the cell markers with one another ( Supplementary Fig. 6 , Supplementary Text), leading to the possibility of overcorrection under the comprehensive model. All CEMs were annotated for enrichment of cell-type expressed genes, which are primarily expressed in one of five human brain cell types [18] (Supplementary Tables 12-16 ) and which are sufficient to differentiate the cell populations from one another (Supplementary Figs. 7 and 8) .
Results are provided for the TCX CEM in the discovery cohort under the comprehensive (Supplementary  Tables 17-20) and simple models (Supplementary  Tables 21-24 ) for all pairwise diagnostic groups. CEM naming conventions are shown in Supplementary Table 25.
In the AD 1 PSP cohort, 44 TCX consensus CEMs were identified under the comprehensive model of which 12 had significant enrichment for one of the five brain cell-enriched gene sets (Supplementary Table 18 ). Using the simple model, 31 such TCX CEMs were identified, of which 10 had enrichment for brain cell-enriched genes (Supplementary Table 22 ). The TCX CEMs generated under the comprehensive and simple models were well preserved (Supplementary Figs. 9 and 10). Table 1 shows those TCX CEMs in the AD 1 PSP discovery cohort that had significant brain cell-enrichment under both analytic models ( Supplementary Figs. 9-11 
Myelination CEMs have replicable neurodegenerative disease association in the TCX
We tested the association of network modules with neuropathologic diagnoses. Under the simple model, there were 17 CEMs that had significant DE in the TCX of AD versus PSP subjects in the discovery cohort (Supplementary  Table 22 ), of which seven also had brain cell enrichment (Fig. 1A , Table 1 ). In contrast, under the comprehensive model, there were only nine TCX CEMs with disease association (Supplementary Table 18 ), of which four had brain cell enrichment (Fig. 1B , Table 1 ). None of the CER CEMs with brain cell enrichment had significant association with disease (Table 2) , despite being well preserved with the TCX modules.
Inspection of the TCX CEMs with disease association and cell enrichment under both analytic models revealed that only the modules enriched in oligodendrocyte transcripts, implicated in myelination, had strong preservation under the simple ( Fig. 2A and B, AD1PSP TCX11.CS simple , AD1PSP TCX29.CS simple ) and comprehensive models ( Fig. 2C and D, AD1PSP TCX10.CS, AD1PSP TCX40.CS). Henceforth, we refer to these CEMs and others with oligodendrocyte-transcript enrichment as "myelination modules." All four myelination modules had higher levels of expression in TCX of AD subjects compared with PSP (Table 1 , Fig. 1A 4 , A 9 , B 3 , B 9 ). This remarkably consistent association of myelination networks with disease irrespective of adjustment for five brain cell-type specific expression markers suggested that these networks may be differentially regulated in AD versus PSP for reasons other than brain cell population changes. No other TCX brain cell-enriched modules had consistent direction of association with disease under both analytic models.
For these reasons, we focused on the myelination modules in the independent "Mayo Clinic RNAseq" replication cohort [16] . After QC of this cohort ( Supplementary Figs. 18-21 ), Abbreviations: AD, Alzheimer's disease; GO, gene ontology; OR, odds ratio; PSP, progressive supranuclear palsy; TCX, temporal cortex. NOTE. Weighted gene coexpression network analysis consensus modules are generated from the discovery cohort's whole genome complementary DNA-mediated annealing, selection, extension, and ligation transcript data obtained from the TCX. Results are shown both for the simple module (no correction for cell type variation) and the comprehensive model (corrects for cell type variation). Modules that have significant cell type enrichment under both models are shown. The modules that significantly associate with diagnosis in the AD versus PSP comparisons are given in bold. Disease association beta 5 coefficient of association with AD diagnosis, that is, positive beta 5 increased in AD. Cell type enrichment P value is Bonferroni-corrected. Top GO Biological Process (BP) 5 gene ontology BP with the most significant enrichment in the module is shown. Top GO enrichment P value is Bonferroni-corrected. expression measures were retained for 80 AD and 82 PSP subjects, as well as 76 elderly control subjects. The 13,273 TCX RNAseq transcripts (13,211 unique genes), which overlapped with those from the discovery cohort, were used in all downstream analyses. In the coexpression network AD versus PSP analyses of the replication cohort, one myelination module was identified under the simple model (Table 3 The simple model myelination module ( AD1PSP TCX3. CSRS simple ) was highly preserved with the corresponding modules from the discovery cohort (Supplementary Figs. 22 and 23) and had significantly higher transcript levels in AD subjects compared with PSP (Table 3) . The direction and effect size of disease association for myelination modules between these independent cohorts were remarkably similar (Tables 1 and 3 ). In contrast, none of the three myelination CEMs in the replication cohort under the comprehensive model showed disease association in the AD versus PSP (Table 3) , unlike the corresponding analysis in the discovery cohort (Table 1) .
To distinguish whether the higher levels of myelination networks in AD versus PSP TCX are because of an upregulation in AD or more downregulation in PSP brains, we compared the elderly control brain tissue in the replication cohort against either AD or PSP TCX transcriptome. Under the simple model, we identified two myelination CEMs each in the AD 1 control and PSP 1 control analyses. Both PSP 1 control (Table 3, PSP1Con TCX5 .CSRS simple , PSP1Con TCX12. CSRS simple ) TCX CEMs were significantly lower in PSP. Under the comprehensive model, there were four AD 1 control and two PSP 1 control myelination CEMs. Interestingly, all these modules showed lower myelination network levels in both neurodegenerative disease groups in comparison to control subjects, one of which achieved statistical significance (Table 3 , AD1Con TCX7.CSRS).
Together with the results from the discovery cohort, these findings suggest that myelination networks are downregulated in both AD and PSP compared with control subjects, but are more downregulated in PSP. For the replication cohort, the network associations with PSP are more pronounced in the simple model, whereas those for AD are more pronounced in the comprehensive model. Nevertheless, levels of the oligodendrocyte marker OLIG2 are not significantly different between diagnostic groups (Supplementary Fig. 4C ). Therefore, downregulation of myelination networks in these diseases cannot be entirely explained by oligodendrocyte cell population changes (Supplementary Text).
Myelination CEMs harbor neurodegenerative disease risk genes with replicable differential expression
To investigate the genes from the myelination modules further, we focused on a subset that have the highest MM; in addition to genes that are implicated in the pathophysiology of AD [32, 33] , PSP [34] , or in myelin biology [35] (Supplementary Results, Table 4 ). We evaluated the AD versus PSP differential expression of these individual transcripts in the discovery and replication cohorts, under the simple and comprehensive models. We also performed DGE analyses for all other pairwise diagnostic comparisons (Supplementary Table 34) .
MM values close to 1 reflect high connectivity of the gene to the module [14] . The MM values of these genes were generally high (.0.70) and similar in all analyses (Table 4) . Under the simple model, all 20 genes had higher levels in AD compared with PSP TCX in both cohorts, with remarkably consistent effect estimates. All 20 transcript associations were significant in the discovery and eight in the replication cohort, including disease implicated genes PSEN1, SLCO1A2, and CR1. Under the comprehensive model, in the discovery cohort, all 20 genes had higher TCX level estimates in AD subjects versus PSP, 14 of which were statistically significant. In the replication cohort, none of the associations were retained under the comprehensive model, suggesting that cell-type adjustment may be accounting for a larger portion of the diagnostic differences for these genes in this cohort.
To determine whether the transcriptional changes observed in the TCX were also reflected in protein levels, we sought to validate these findings by performing Western blot analyses in TCX samples (Supplementary Table 35 , Supplementary Fig. 24 ). Given the limited dynamic range for quantitation of blots labeled with horseradish peroxidase (HRP)-tagged antibodies, as in our study, these Western blots should be considered as semiquantitative. Despite significant variability, all myelin proteins had lower levels in PSP TCX ( Supplementary Fig. 24A -F) consistent with the transcript results, although these trends did not reach statistical significance, likely because of the relatively small sample size of this protein analysis cohort. All myelin proteins except myelin oligodendrocyte glycoprotein (MOG) and plasmolipin (PLLP) had lower level estimates in AD TCX (Supplementary Fig. 24 .G-L), but not statistically significant, highlighting the need to evaluate much larger cohorts for protein validations.
Using proteome data from a larger cohort of 84 AD and 83 PSP TCX samples, obtained with liquid chromatography coupled with tandem mass spectrometry analysis, we identified significantly lower protein levels for myelin basic protein (MBP) and 2',3'-cyclic nucleotide 3' phosphodiesterase (CNP) in PSP compared with AD TCX, and lower estimates that did not reach statistical significance for MOG, myelin proteolipid protein (PLP1), and bridging integrator 1 (BIN1) (Supplementary Table 36 ). As expected, glial fibrillary acidic protein (GFAP), amyloid precursor protein (APP), and microtubule associated protein tau (MAPT) protein levels were lower in PSP compared with AD TCX.
We assessed myelination patterns, as well as microgliosis and astrogliosis in a subset of AD, PSP, and control TCX samples (Supplementary Table 37 , Supplementary Fig. 25 ). As expected, there is variability in the level of pathology. Given this and the small number of samples assessed, statistical differences in quantitative neuropathology cannot be detected. Nevertheless, the pattern of reduced myelination can be appreciated in select AD and PSP versus control TCX samples. We evaluated immunocytochemical patterns for the myelin and oligodendrocyte proteins in rat primary modules in the replication cohort under the comprehensive model were significantly associated with disease. The circles or squares represent the nodes for the genes within the CEM. For each module, the top 150 connections according to topological overlap matrices weight are shown for genes with a MM .0.7. The size of a node correlates with the number of connections for that node with others within the network. Gene transcripts that are enriched within oligodendrocytes are shown in orange. Transcripts with significant differential expression at q , 0.05 are shown as a square. Thickness of the connection lines is determined by the weight of the connection. Abbreviations: AD, Alzheimer's disease; CEMs, coexpression modules; PSP, progressive supranuclear palsy. Abbreviations: AD, Alzheimer's disease; PSP, progressive supranuclear palsy; RNAseq, RNA sequencing; TCX, temporal cortex. Weighted gene coexpression network analysis consensus modules are generated from the replication cohort's RNAseq transcript data obtained from the TCX. This data set is independent from the discovery cohort. Results are shown both for the simple module (no correction for cell types) and the comprehensive model (corrects for cell types). Modules that are significantly enriched for oligodendrocyte-specific genes are shown. There are a total of 99 oligodendrocyte-enriched genes. The number of these that pertain to each module are shown. Disease association beta 5 coefficient of association with AD diagnosis where AD is in the diagnostic comparison, or else for PSP The modules that significantly associate with diagnosis are bolded and suggestive association (P ,.1) is italicized.. 
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Discussion
In this study, we identified highly conserved myelination networks that are altered in both PSP and AD brains but to a greater extent in the former. This study is distinct from prior transcriptome studies in neurodegenerative diseases [3, 5, 6, 36] in several ways. We provide comparison of multiple neurodegenerative conditions, in addition to control subjects; use two independent cohorts; study two brain regions; use two different approaches for measuring gene expression; assess cell population variability; and perform protein validations (Supplementary Discussion). The underlying premise of our approach is that comparative analyses of different neurodegenerative diseases can uncover transcripts and molecular networks that are disease-specific and those that underlie shared aspects of disease pathology. To our knowledge, this is the first study, which has performed a systematic comparison of brain transcriptomes from AD versus a primary tauopathy, PSP. Our conclusions are based on a collective data set of 940 brain transcriptomes.
Our study yields insights into the role of myelination in the pathophysiology of two neurodegenerative diseases. To our knowledge oligodendrocyte/myelination pathways have not been studied comparatively in AD versus PSP at a systemsbiology level. There is evidence from neuropathology that oligodendrocyte/myelination dysfunction could contribute to both AD and PSP. Oligodendroglial tau deposits are a key aspect of PSP neuropathology [12] . Myelin loss was demonstrated in AD white matter (WM) [37] , and focal intracortical demyelination associated with Ab plaques was observed in AD gray matter [38] . Furthermore, human brain myelination has distinct aspects that may predispose it to vulnerabilities resulting in neuropsychiatric illness [35, 39] . Myelination in humans is an evolutionarily late event, which is distinguished from that of other species by its extent in both gray matter and WM and by developmental myelination extending well into middle ages [35] .
We find that brain gene expression networks enriched in oligodendrocyte transcripts involved in myelination are downregulated in PSP compared with AD. This downregulation is observed in two independent cohorts and is retained in the discovery cohort, even after adjusting for cell-specific markers (comprehensive model) to account for any cell population changes. The similarity in the findings in the discovery cohort under both the simple and comprehensive models suggests that the transcriptional changes are unlikely to be solely because of cell population changes. This is further corroborated by the fact that TCX, where these transcriptional changes are observed, is a region typically unaffected by PSP pathology [12] . Myelination networks are also downregulated in PSP TCX in comparison to control subjects, providing further support that these transcriptional changes are unlikely to be because of gross changes in pathology. The depression of these findings under the comprehensive model in the replication, but not the discovery cohort, may be multifactorial. First, the latter has .50% greater sample size. Second, RNAseq measures in the replication cohort may provide a more precise measurement of gene levels that may have led to better adjustment for cell type changes or overcorrection because of their stronger intercorrelation.
Importantly, there is downregulation of myelin proteins in PSP TCX in protein data from 167 brain samples assessed by liquid chromatography coupled with tandem mass spectrometry and a smaller cohort evaluated by semiquantitative Western blots analysis. Myelination patterns and cellular specificity of the antibodies used to assess myelination proteins are demonstrated by immunohistochemistry and immunocytochemistry in human brains and rat primary oligodendrocyte-enriched cultures. Thus, our transcriptome findings are also corroborated by protein data.
Our study paradigm allowed us to distinguish that myelination networks may also be downregulated in AD, but to a lesser extent than in PSP, rather than simply being upregulated in AD versus PSP. This lesser alteration in AD TCX is intriguing, especially given that AD, unlike PSP, has significant pathology in TCX [9] . This finding further implies that the myelination network changes are unlikely to be a mere consequence of pathology. The enhanced vulnerability of myelination networks in PSP, in comparison to AD, leads to a number of compelling hypotheses. Both AD and PSP are characterized by aggregates of tau, which is a microtubuleassociated protein and a constituent of both neurons and oligodendrocytes [13, 39] . Microtubules and tau are integral to oligodendroglial function and myelination, which are disrupted when tau is either overexpressed or downregulated. Hence, alteration of myelination networks in both AD and PSP is consistent with these data.
A key question is why this alteration is more enhanced in PSP in a brain region far less affected than in AD. One explanation may be the difference in the type of tau aggregate, with PSP harboring 4R-tau aggregates, composed of a tau isoform with four microtubule-binding domains, whereas AD has both 3R-tau and 4R-tau aggregates. In cultured oligodendrocytes, 4R-tau becomes increased and 3R-tau decreased with development [39] . We can therefore postulate that myelination pathways may be more vulnerable to 4R-tauopathies, such as PSP. Another reason may be the presence of genetic risk factors in PSP with a role in myelination. Indeed, variants in/near MOBP are implicated in risk of PSP [34] and CBD [40] , another 4R-tauopathy. MOBP encodes the CNS-expressed myelin-associated oligodendrocytic basic protein, which is a member of the myelination networks identified herein.
Another finding from our study is the remarkable conservation of brain transcriptional networks that are independently constructed in two brain regions, TCX and CER. This finding is consistent with the prior observations in healthy control brains [41] and suggests that the broad architecture of the brain transcriptional networks is unlikely to be driven by cell population differences in disease-affected versus unaffected tissue. In addition, although we focused on myelination networks in this study, we identified modules enriched in astrocytic, microglial, and neuronal transcripts, which show consistencies with prior transcriptome studies [6, 36, 42] . The detailed findings from our analyses that we present here and the accessibility of our large-scale data [16] should establish this study as a highly useful resource.
In summary, our study identifies downregulation of myelination networks as a potential pathophysiological component of both PSP and AD. Our findings are based on postmortem brain tissue, which reflects a "snapshot" of gene expression networks for end-stage disease. Nevertheless, this work can be instrumental in launching future biomarker or therapeutic discovery efforts. Neuroimaging studies in living patients support WM [43, 44] and specifically myelin alterations [45] in preclinical AD. Key molecules within myelination networks identified in our study can serve to develop novel molecular imaging tools for tracking myelin neuropathology in longitudinal cohorts followed for incident AD and other neurodegenerative diseases. Such cohorts should also enable detection of longitudinal changes in gene and protein expression levels for these molecules, which can help establish their temporal relationship with cognitive and other clinical outcomes. These future studies can provide fundamental new insight into the role of myelin dysregulation in the cascade of pathophysiological processes in AD [46] and other neurodegenerative conditions. In addition, the specific expression network alterations uncovered in our study can be tested in model systems for their potential as therapeutic targets. There are known interactions between oligodendrocytes and the other CNS cell types, including inflammatory and astrocytic activation in myelin breakdown and remyelination [35] . We find that established and candidate AD genes [33] , such as PSEN1, BIN1, and CR1, reside in myelination modules. Given these and the effects of both tau [12, 39] and Ab [37, 38] on myelination, we posit that myelin may indeed be the "glue" that holds together key biological functions in the adult brain, the disruption of which results in neuropsychiatric conditions such as AD and PSP. 
Supplementary data
Supplementary data related to this article can be found at https://doi.org/10.1016/j.jalz.2017.09.012.
RESEARCH IN CONTEXT
1. Systemic review: Reviewing the literature for gene expression profiling publications of neuroproteinopathies showed that most studies are limited to small cohorts and individual gene transcript rather than systems-level analysis. Furthermore, most studies assess one disease group against control subjects rather than comparative transcriptome analyses of different diseases.
2. Interpretation: Comparative transcriptome analyses in Alzheimer's disease (AD) and other neurodegenerative proteinopathies can uncover both shared and distinct disease pathways. Our analysis of 940 brain transcriptomes including patients with AD, progressive supranuclear palsy, and control subjects identified downregulation of myelination networks in both AD and progressive supranuclear palsy, but more pronounced in the latter.
3. Future directions: Future studies should investigate in antemortem cohorts, longitudinal changes in myelination network molecules to determine their role in the pathophysiological processes in AD and other neurodegenerative diseases with a goal to establish them as novel biomarkers. The myelination network molecules should be tested in model systems for their potential as therapeutic targets.
